Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain surgery sedation: do current dosing models work in the ICU?

NCT ID NCT06584097

First seen Feb 16, 2026 · Last updated Jun 23, 2026 · Updated 22 times

Summary

This study checks whether computer models that help doctors dose the sedatives propofol and remifentanil during brain surgery also work well when patients are in the intensive care unit afterward. Researchers will compare how accurate the models are in the ICU versus during surgery. The goal is to see if these models can be used to guide sedation after surgery, potentially improving patient comfort and safety.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROSURGICAL PATIENTS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fondazione IRCCS Istituto Neurologico C. Besta

    RECRUITING

    Milan, Milano, 20133, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Foundation IRCCS Carlo Besta Neurological Institute

    RECRUITING

    Milan, Italy, 20133, Italy

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

propofol and remifentanil

What this could lead to

If successful, this could improve how doctors dose these sedatives in the ICU after brain surgery, making care safer and more personalized.

What could go wrong

This is a small, early-stage study with only 42 participants, so results may not apply to all patients. It measures drug levels, not direct patient outcomes.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.